Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel®) for up to 1 year

Journal of Dermatological Treatment

Volumn 18, Issue 1, 2007, Pages 19-22

  Van Leent, Edwin J M ^a,b   De Vries, Henry J C ^a,b   Ebelin, Marie Eve ^c   Burtin, Pascale ^c   Scott, Graham ^c   Bos, Jan D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Elidel; Pharmacokinetics; Pimecrolimus

Indexed keywords

PIMECROLIMUS;

ADULT; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; BIOACCUMULATION; BLOOD SAMPLING; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRY SKIN; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY;

ADMINISTRATION, CUTANEOUS; ADULT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33947181932     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601121037     Document Type: Article

References (9)

1. Paul C, Graeber M, Stuetz A. Ascomycins: Promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs. 2000;9:69-77.
2. Van Leent EJM, Gräber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134:805-9.
3. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: A non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003;111:1154-68.
4. Wellington K, Noble N. Pimecrolimus: A review of its use in atopic dermatitis. Am J Clin Dermatol. 2004;5:479-95.
5. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005;6:65-77.
6. Van Leent E, Ebelin ME, Burtin P, Dorobek B, Spuls P, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204:63-8.
7. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-7.
8. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-18.
9. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 2002;119:876-87.